PriceTargets.com logo

ReShape Lifesciences - RSLS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $8.00
  • Forecasted Upside: 4,586.58%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.17 As of 04/18/2024 01:00 AM ET
▲ +0.01 (6.22%)

This chart shows the closing price for RSLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ReShape Lifesciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RSLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RSLS

Analyst Price Target is $8.00
▲ +4,586.58% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for ReShape Lifesciences in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 4,586.58% upside from the last price of $0.17.

This chart shows the closing price for RSLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in ReShape Lifesciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2023Maxim GroupLower Target$50.00 ➝ $8.00Low
8/17/2022Alliance Global PartnersLower Target$232.50 ➝ $87.50Low
5/26/2022Alliance Global PartnersBoost TargetBuy ➝ Buy$232.50 ➝ $275.00High
3/29/2022Maxim GroupLower Target$400.00 ➝ $200.00High
11/12/2021Maxim GroupReiterated RatingBuy$400.00High
10/8/2021Maxim GroupInitiated CoverageBuy$400.00High
8/20/2021Alliance Global PartnersReiterated RatingBuy$687.50 ➝ $512.50Low
7/1/2021Alliance Global PartnersLower TargetBuy$925.00 ➝ $687.50Medium
6/17/2021Alliance Global PartnersBoost TargetBuy$600.00 ➝ $925.00High
2/18/2021Alliance Global PartnersInitiated CoverageBuyMedium
(Data available from 4/19/2019 forward)

News Sentiment Rating

-0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
ReShape Lifesciences logo
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Read More

Today's Range

Now: $0.17
Low: $0.16
High: $0.18

50 Day Range

MA: $0.17
Low: $0.15
High: $0.19

52 Week Range

Now: $0.17
Low: $0.14
High: $3.43

Volume

430,864 shs

Average Volume

404,528 shs

Market Capitalization

$2.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

Frequently Asked Questions

What sell-side analysts currently cover shares of ReShape Lifesciences?

The following Wall Street sell-side analysts have issued reports on ReShape Lifesciences in the last twelve months: Maxim Group.
View the latest analyst ratings for RSLS.

What is the current price target for ReShape Lifesciences?

1 Wall Street analysts have set twelve-month price targets for ReShape Lifesciences in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 4,586.6%. Maxim Group has the highest price target set, predicting RSLS will reach $8.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $8.00 for ReShape Lifesciences in the next year.
View the latest price targets for RSLS.

What is the current consensus analyst rating for ReShape Lifesciences?

ReShape Lifesciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RSLS.

What other companies compete with ReShape Lifesciences?

Other companies that are similar to ReShape Lifesciences include Nemaura Medical, Quoin Pharmaceuticals, Bluejay Diagnostics, Dynatronics and Tenon Medical. Learn More about companies similar to ReShape Lifesciences.

How do I contact ReShape Lifesciences' investor relations team?

ReShape Lifesciences' physical mailing address is 1001 Calle Amanecer, San Clemente CA, 92673. The medical device company's listed phone number is (949) 429-6680 and its investor relations email address is [email protected]. The official website for ReShape Lifesciences is www.reshapelifesciences.com. Learn More about contacing ReShape Lifesciences investor relations.